179 related articles for article (PubMed ID: 1976142)
1. The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers.
Oster G; Huse DM; Delea TE; Colditz GA; Richter JM
Med Care; 1990 Sep; 28(9):834-52. PubMed ID: 1976142
[TBL] [Abstract][Full Text] [Related]
2. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use.
Kalish SC; Bohn RL; Avorn J
Med Care; 1997 Jan; 35(1):32-48. PubMed ID: 8998201
[TBL] [Abstract][Full Text] [Related]
3. Over-the-counter histamine2-blocker therapy.
Gonzalez ER; Grillo JA
Ann Pharmacother; 1994 Mar; 28(3):392-5. PubMed ID: 7910767
[TBL] [Abstract][Full Text] [Related]
4. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists.
Andrade SE; Gurwitz JH; Fish LS
Med Care; 1999 Apr; 37(4):424-30. PubMed ID: 10213023
[TBL] [Abstract][Full Text] [Related]
5. Self-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonists.
Shaw MJ; Fendrick AM; Kane RL; Adlis SA; Talley NJ
Am J Gastroenterol; 2001 Mar; 96(3):673-6. PubMed ID: 11280532
[TBL] [Abstract][Full Text] [Related]
6. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
Tasch RF; Goeree R; Henke CJ; O'Brien BJ
Pharmacoeconomics; 1996 Jan; 9(1):61-75. PubMed ID: 10160088
[TBL] [Abstract][Full Text] [Related]
7. General practitioners' views on the over-the-counter availability of H2-antagonists.
Erwin J; Britten N; Jones R
Br J Gen Pract; 1997 Feb; 47(415):99-102. PubMed ID: 9101694
[TBL] [Abstract][Full Text] [Related]
8. Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.
Hunt RH
CMAJ; 1996 Jan; 154(1):49-53. PubMed ID: 8542566
[TBL] [Abstract][Full Text] [Related]
9. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
Shih YC; Prasad M; Luce BR
Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
[TBL] [Abstract][Full Text] [Related]
10. Over-the-Counter Medications in Pregnancy.
Servey J; Chang J
Am Fam Physician; 2014 Oct; 90(8):548-55. PubMed ID: 25369643
[TBL] [Abstract][Full Text] [Related]
11. Nonprescription H2-receptor antagonists.
Marsh TD
J Am Pharm Assoc (Wash); 1997; NS37(5):552-6. PubMed ID: 9479407
[TBL] [Abstract][Full Text] [Related]
12. Treatment of gastroesophageal reflux disease.
Pettit M
Pharm World Sci; 2005 Dec; 27(6):432-5. PubMed ID: 16341949
[TBL] [Abstract][Full Text] [Related]
13. Consumer usage patterns of nonprescription histamine2-receptor antagonists.
Shi CW; Gralnek IM; Dulai GS; Towfigh A; Asch S
Am J Gastroenterol; 2004 Apr; 99(4):606-10. PubMed ID: 15089889
[TBL] [Abstract][Full Text] [Related]
14. Self-medication of dyspepsia: how appropriate is it?
Sihvo S; Hemminki E
Scand J Gastroenterol; 1997 Sep; 32(9):855-61. PubMed ID: 9299660
[TBL] [Abstract][Full Text] [Related]
15. Drug utilization evaluation of nonprescription H2-receptor antagonists and alginate-containing preparations for dyspepsia.
Krska J; John DN; Hansford D; Kennedy EJ
Br J Clin Pharmacol; 2000 Apr; 49(4):363-8. PubMed ID: 10759692
[TBL] [Abstract][Full Text] [Related]
16. From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006-2015: pharmacological perspectives on regulatory decisions.
Barrenberg E; Garbe E
Eur J Clin Pharmacol; 2017 Jul; 73(7):901-910. PubMed ID: 28352949
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
Trygstad TK; Hansen RA; Wegner SE
J Manag Care Pharm; 2006 Mar; 12(2):108-20. PubMed ID: 16515369
[TBL] [Abstract][Full Text] [Related]
18. Over-the-counter nonsteroidal anti-inflammatory drugs and risk of gastrointestinal symptoms.
Thomas J; Straus WL; Bloom BS
Am J Gastroenterol; 2002 Sep; 97(9):2215-9. PubMed ID: 12358235
[TBL] [Abstract][Full Text] [Related]
19. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial.
van Marrewijk CJ; Mujakovic S; Fransen GA; Numans ME; de Wit NJ; Muris JW; van Oijen MG; Jansen JB; Grobbee DE; Knottnerus JA; Laheij RJ
Lancet; 2009 Jan; 373(9659):215-25. PubMed ID: 19150702
[TBL] [Abstract][Full Text] [Related]
20. Over the counter H2 receptor antagonists. Serve only as expensive antacids.
Douds AC; Maxwell JD
BMJ; 1994 Oct; 309(6962):1156. PubMed ID: 7987114
[No Abstract] [Full Text] [Related]
[Next] [New Search]
